

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 3rd May 2023.

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **OG** - Second line / alternative green drug.
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
Nil				
2) New Requests				
Estradiol 10 microgram vaginal tablets (Vagirux®) for treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women	✓ G			Requested for treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women. This currently the cheapest and most environmentally sustainable brand available. Decision: approved as a GREEN drug and to be listed as the brand of choice as has less plastic waste than other brands.
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA875: Semaglutide for managing overweight and obesity			✓	Decision deferred until product is launched in UK and price is known so accurate local cost impact can be calculated.
TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer	R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA877: Finerenone for treating chronic kidney disease in type 2 diabetes			✓	Decision deferred till next month to get accurate local patient numbers and consult with renal team.
TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19	✓ R			The formulary will reflect the TAG – ICS is the responsible commissioner.
HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Dexcom ONE	✓ ASI			Decision: to ask ICB to update current Flash/CG policy to commission Dexcom One for all patients who were previously eligible on the Freestyle Libre (FSL) commissioning position. Since these patients are already eligible for FSL, they would also be eligible for Dexcom One, and there would be no financial impact in doing so since both devices are of the same cost. This may also allow patients access to an alternative device prior to other specialist CGM devices provided via the hospital.

The following guidelines were presented to and approved at the May 2023 meeting of the APC:

- Nil this month.

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the May 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the May 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the May 2023 meeting of the APC for comment:

- Nil this month.